Sign In
Buy OTLK
$0.98
-0.0634 (-6.10%)
At Close: Jul 31, 2026
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
08:35am, Wednesday, 03'rd Sep 2025
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of
Outlook Therapeutics Requests Type A Meeting with FDA
08:35am, Tuesday, 02'nd Sep 2025
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of
OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug
11:41am, Friday, 29'th Aug 2025
Outlook Therapeutics stock plunges 54% after the FDA rejects ONS-5010 BLA again, citing lack of efficacy data in confirmatory study.
Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug
11:51am, Thursday, 28'th Aug 2025
Shares of Outlook Therapeutics fell sharply on Thursday after the US Food and Drug Administration (FDA) rejected the company's application for its experimental eye drug ONS-5010, a proposed treatment
FDA Rejects Outlook Therapeutics Eye Drug For Second Time
11:15am, Thursday, 28'th Aug 2025
Outlook Therapeutics, Inc. OTLK stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.
US FDA declines to approve Outlook Therapeutics' drug for eye condition
06:39am, Thursday, 28'th Aug 2025
The U.S. Food and Drug Administration has declined to approve Outlook Therapeutics' experimental drug to treat a type of eye condition that causes blurred vision, the company said on Thursday.
ISELIN, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision
09:15am, Sunday, 24'th Aug 2025
FDA approval for Lytenava might come next week, I see Outlook Therapeutics at a pivotal inflection point, offering a rare asymmetric risk/reward setup. Lytenava's European approval, decade-long exclus
Oncobiologics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates
10:16am, Thursday, 14'th Aug 2025
Oncobiologics, Inc. (OTLK) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.83 per share a year ago.
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
08:05am, Thursday, 14'th Aug 2025
ISELIN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
New Strong Buy Stocks for July 30th
06:50am, Wednesday, 30'th Jul 2025
BYD, ROKU, OTLK, E and PII have been added to the Zacks Rank #1 (Strong Buy) List on July 30, 2025.
Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
09:00am, Thursday, 24'th Jul 2025
ISELIN, N.J., July 24, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference
08:45am, Tuesday, 22'nd Jul 2025
Video webcast now available on-demand ISELIN, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care f
Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer
08:05am, Tuesday, 01'st Jul 2025
Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies
Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event
09:05am, Wednesday, 18'th Jun 2025
ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of re
